Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 605

1.

Development and Characterization of a Novel, High-Affinity, Specific, Radiolabeled Ligand for BRS-3 Receptors.

Ramos-Alvarez I, Lee L, Mantey SA, Jensen RT.

J Pharmacol Exp Ther. 2019 Jun;369(3):454-465. doi: 10.1124/jpet.118.255141. Epub 2019 Apr 10.

2.

Cyclic AMP-dependent protein kinase A and EPAC mediate VIP and secretin stimulation of PAK4 and activation of Na+,K+-ATPase in pancreatic acinar cells.

Ramos-Alvarez I, Lee L, Jensen RT.

Am J Physiol Gastrointest Liver Physiol. 2019 Feb 1;316(2):G263-G277. doi: 10.1152/ajpgi.00275.2018. Epub 2018 Dec 6.

PMID:
30520694
3.

Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms.

Jensen RT, Bodei L, Capdevila J, Couvelard A, Falconi M, Glasberg S, Kloppel G, Lamberts S, Peeters M, Rindi G, Rinke A, Rothmund M, Sundin A, Welin S, Fazio N; The ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants.

Neuroendocrinology. 2019;108(1):26-36. doi: 10.1159/000494258. Epub 2018 Oct 3.

PMID:
30282083
4.

PAC1 regulates receptor tyrosine kinase transactivation in a reactive oxygen species-dependent manner.

Moody TW, Lee L, Iordanskaia T, Ramos-Alvarez I, Moreno P, Boudreau HE, Leto TL, Jensen RT.

Peptides. 2018 Sep 28. pii: S0196-9781(18)30174-8. doi: 10.1016/j.peptides.2018.09.005. [Epub ahead of print]

PMID:
30273693
5.

Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms.

Capdevila J, Bodei L, Davies P, Gorbounova V, Jensen RT, Knigge UP, Krejs GJ, Krenning E, O'Connor JM, Peeters M, Rindi G, Salazar R, Vullierme MP, Pavel ME; ENETS 2016 Munich Advisory Board Participants; ENETS 2016 Munich Advisory Board Participants.

Neuroendocrinology. 2019;108(1):18-25. doi: 10.1159/000493319. Epub 2018 Aug 28.

6.

Gastrinomas: Medical or Surgical Treatment.

Norton JA, Foster DS, Ito T, Jensen RT.

Endocrinol Metab Clin North Am. 2018 Sep;47(3):577-601. doi: 10.1016/j.ecl.2018.04.009. Review.

PMID:
30098717
7.

Neuropeptide G Protein-Coupled Receptors as Oncotargets.

Moody TW, Ramos-Alvarez I, Jensen RT.

Front Endocrinol (Lausanne). 2018 Jun 29;9:345. doi: 10.3389/fendo.2018.00345. eCollection 2018. Review.

8.

Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies.

Lee L, Ito T, Jensen RT.

Expert Rev Anticancer Ther. 2018 Sep;18(9):837-860. doi: 10.1080/14737140.2018.1496822. Epub 2018 Jul 17. Review.

PMID:
29973077
9.

Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence.

Lee L, Ito T, Jensen RT.

Expert Opin Pharmacother. 2018 Jun;19(8):909-928. doi: 10.1080/14656566.2018.1476492. Epub 2018 May 24.

10.
11.

Prospective Evaluation of Results of Reoperation in Zollinger-Ellison Syndrome.

Norton JA, Krampitz GW, Poultsides GA, Visser BC, Fraker DL, Alexander HR, Jensen RT.

Ann Surg. 2018 Apr;267(4):782-788. doi: 10.1097/SLA.0000000000002122.

PMID:
29517561
12.

Design, synthesis and biological evaluation of hybrid nitroxide-based non-steroidal anti-inflammatory drugs.

Thomas K, Moody TW, Jensen RT, Tong J, Rayner CL, Barnett NL, Fairfull-Smith KE, Ridnour LA, Wink DA, Bottle SE.

Eur J Med Chem. 2018 Mar 10;147:34-47. doi: 10.1016/j.ejmech.2018.01.077. Epub 2018 Jan 31.

PMID:
29421569
13.

A possible new target in lung-cancer cells: The orphan receptor, bombesin receptor subtype-3.

Moreno P, Mantey SA, Lee SH, Ramos-Álvarez I, Moody TW, Jensen RT.

Peptides. 2018 Mar;101:213-226. doi: 10.1016/j.peptides.2018.01.016. Epub 2018 Feb 2.

14.

Activation of bombesin receptor Subtype-3 by [D-Tyr6,β-Ala11,Phe13,Nle14]bombesin6-14 increased glucose uptake and lipogenesis in human and rat adipocytes.

Moreno-Villegas Z, Martín-Duce A, Aparicio C, Portal-Núñez S, Sanz R, Mantey SA, Jensen RT, Lorenzo O, Egido J, González N.

Mol Cell Endocrinol. 2018 Oct 15;474:10-19. doi: 10.1016/j.mce.2018.01.028. Epub 2018 Jan 31.

PMID:
29402494
15.

Incidence and Prognosis of Primary Gastrinomas in the Hepatobiliary Tract.

Norton JA, Foster DS, Blumgart LH, Poultsides GA, Visser BC, Fraker DL, Alexander HR, Jensen RT.

JAMA Surg. 2018 Mar 1;153(3):e175083. doi: 10.1001/jamasurg.2017.5083. No abstract available.

16.

Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing.

Metz DC, Cadiot G, Poitras P, Ito T, Jensen RT.

Int J Endocr Oncol. 2017;4(4):167-185. doi: 10.2217/ije-2017-0018. Epub 2017 Oct 11.

17.

Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors.

Lee L, Ito T, Igarashi H, Miki M, Fujimori N, Kawabe K, Jensen RT, Ogawa Y.

Cancer Chemother Pharmacol. 2018 Jan;81(1):163-169. doi: 10.1007/s00280-017-3482-7. Epub 2017 Nov 21.

PMID:
29164297
18.

Carcinoid-syndrome: recent advances, current status and controversies.

Ito T, Lee L, Jensen RT.

Curr Opin Endocrinol Diabetes Obes. 2018 Feb;25(1):22-35. doi: 10.1097/MED.0000000000000376. Review.

19.

AM-37 and ST-36 Are Small Molecule Bombesin Receptor Antagonists.

Moody TW, Tashakkori N, Mantey SA, Moreno P, Ramos-Alvarez I, Leopoldo M, Jensen RT.

Front Endocrinol (Lausanne). 2017 Jul 21;8:176. doi: 10.3389/fendo.2017.00176. eCollection 2017.

20.

Treatment of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1: Some Clarity But Continued Controversy.

Jensen RT, Norton JA.

Pancreas. 2017 May/Jun;46(5):589-594. doi: 10.1097/MPA.0000000000000825. No abstract available.

21.

ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Biochemical Markers.

Oberg K, Couvelard A, Delle Fave G, Gross D, Grossman A, Jensen RT, Pape UF, Perren A, Rindi G, Ruszniewski P, Scoazec JY, Welin S, Wiedenmann B, Ferone D; Antibes Consensus Conference participants.

Neuroendocrinology. 2017;105(3):201-211. doi: 10.1159/000472254. Epub 2017 Apr 8. No abstract available.

22.

Utility of chromogranin B compared with chromogranin A as a biomarker in Japanese patients with pancreatic neuroendocrine tumors.

Miki M, Ito T, Hijioka M, Lee L, Yasunaga K, Ueda K, Fujiyama T, Tachibana Y, Kawabe K, Jensen RT, Ogawa Y.

Jpn J Clin Oncol. 2017 Jun 1;47(6):520-528. doi: 10.1093/jjco/hyx032.

23.

Diagnostic Performance of 48-Hour Fasting Test and Insulin Surrogates in Patients With Suspected Insulinoma.

Ueda K, Kawabe K, Lee L, Tachibana Y, Fujimori N, Igarashi H, Oda Y, Jensen RT, Takayanagi R, Ito T.

Pancreas. 2017 Apr;46(4):476-481. doi: 10.1097/MPA.0000000000000772.

PMID:
28230660
24.

Endothelin causes transactivation of the EGFR and HER2 in non-small cell lung cancer cells.

Moody TW, Ramos-Alvarez I, Moreno P, Mantey SA, Ridnour L, Wink D, Jensen RT.

Peptides. 2017 Apr;90:90-99. doi: 10.1016/j.peptides.2017.01.012. Epub 2017 Jan 31.

25.

Antifibrotic Effect of Saturated Fatty Acids via Endoplasmic Reticulum Stress Response in Rat Pancreatic Stellate Cells.

Lee L, Ito T, Nakamura T, Jensen RT, Igarashi H, Takayanagi R.

Pancreas. 2017 Mar;46(3):385-394. doi: 10.1097/MPA.0000000000000757.

26.

Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.

Ito T, Jensen RT.

Curr Opin Endocrinol Diabetes Obes. 2017 Feb;24(1):15-24. doi: 10.1097/MED.0000000000000300. Review.

27.

Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.

Ito T, Lee L, Jensen RT.

Expert Opin Pharmacother. 2016 Nov;17(16):2191-2205. Epub 2016 Sep 23. Review.

28.

Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan.

Ito T, Hijioka S, Masui T, Kasajima A, Nakamoto Y, Kobayashi N, Komoto I, Hijioka M, Lee L, Igarashi H, Jensen RT, Imamura M.

J Gastroenterol. 2017 Jan;52(1):9-18. doi: 10.1007/s00535-016-1250-9. Epub 2016 Aug 18. Review.

PMID:
27539256
29.

Molecular basis for high affinity and selectivity of peptide antagonist, Bantag-1, for the orphan BB3 receptor.

Nakamura T, Ramos-Álvarez I, Iordanskaia T, Moreno P, Mantey SA, Jensen RT.

Biochem Pharmacol. 2016 Sep 1;115:64-76. doi: 10.1016/j.bcp.2016.06.013. Epub 2016 Jun 23.

30.

Src kinases play a novel dual role in acute pancreatitis affecting severity but no role in stimulated enzyme secretion.

Nuche-Berenguer B, Ramos-Álvarez I, Jensen RT.

Am J Physiol Gastrointest Liver Physiol. 2016 Jun 1;310(11):G1015-27. doi: 10.1152/ajpgi.00349.2015. Epub 2016 Mar 31.

31.

Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment.

Moreno P, Ramos-Álvarez I, Moody TW, Jensen RT.

Expert Opin Ther Targets. 2016 Sep;20(9):1055-73. doi: 10.1517/14728222.2016.1164694. Epub 2016 Mar 28. Review.

32.

The p21-activated kinase, PAK2, is important in the activation of numerous pancreatic acinar cell signaling cascades and in the onset of early pancreatitis events.

Nuche-Berenguer B, Ramos-Álvarez I, Jensen RT.

Biochim Biophys Acta. 2016 Jun;1862(6):1122-36. doi: 10.1016/j.bbadis.2016.02.008. Epub 2016 Feb 18.

33.
34.

ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.

Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, Kos-Kudla B, Kwekkeboom D, Rindi G, Klöppel G, Reed N, Kianmanesh R, Jensen RT; Vienna Consensus Conference participants.

Neuroendocrinology. 2016;103(2):153-71. doi: 10.1159/000443171. Epub 2016 Jan 5. No abstract available.

35.

Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.

Moody TW, Nuche-Berenguer B, Jensen RT.

Curr Opin Endocrinol Diabetes Obes. 2016 Feb;23(1):38-47. doi: 10.1097/MED.0000000000000218. Review.

36.

Limited Parathyroidectomy in Multiple Endocrine Neoplasia Type 1-Associated Primary Hyperparathyroidism: A Setup for Failure.

Nilubol N, Weinstein LS, Simonds WF, Jensen RT, Marx SJ, Kebebew E.

Ann Surg Oncol. 2016 Feb;23(2):416-23. doi: 10.1245/s10434-015-4865-9. Epub 2015 Nov 5.

PMID:
26542588
37.

Novel chiral-diazepines function as specific, selective receptor agonists with variable coupling and species variability in human, mouse and rat BRS-3 receptor cells.

Ramos-Álvarez I, Nakamura T, Mantey SA, Moreno P, Nuche-Berenguer B, Jensen RT.

Peptides. 2016 Jan;75:8-17. doi: 10.1016/j.peptides.2015.10.007. Epub 2015 Oct 31.

38.

Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study.

Lee L, Igarashi H, Fujimori N, Hijioka M, Kawabe K, Oda Y, Jensen RT, Ito T.

Jpn J Clin Oncol. 2015 Dec;45(12):1131-8. doi: 10.1093/jjco/hyv143. Epub 2015 Sep 15.

39.

Multiple Endocrine Neoplasia: Genetics and Clinical Management.

Norton JA, Krampitz G, Jensen RT.

Surg Oncol Clin N Am. 2015 Oct;24(4):795-832. doi: 10.1016/j.soc.2015.06.008. Epub 2015 Jul 27. Review.

40.

Better Survival But Changing Causes of Death in Patients With Multiple Endocrine Neoplasia Type 1.

Norton JA, Krampitz G, Zemek A, Longacre T, Jensen RT.

Ann Surg. 2015 Jun;261(6):e147-8. doi: 10.1097/SLA.0000000000001211. No abstract available.

PMID:
26291955
41.

Bombesin receptor subtype 3 as a potential target for obesity and diabetes.

González N, Moreno P, Jensen RT.

Expert Opin Ther Targets. 2015;19(9):1153-70. doi: 10.1517/14728222.2015.1056154. Epub 2015 Jun 12. Review.

42.

Gastrointestinal hormones/neurotransmitters and growth factors can activate P21 activated kinase 2 in pancreatic acinar cells by novel mechanisms.

Nuche-Berenguer B, Jensen RT.

Biochim Biophys Acta. 2015 Oct;1853(10 Pt A):2371-82. doi: 10.1016/j.bbamcr.2015.05.011. Epub 2015 May 12.

43.

Insights into bombesin receptors and ligands: Highlighting recent advances.

Ramos-Álvarez I, Moreno P, Mantey SA, Nakamura T, Nuche-Berenguer B, Moody TW, Coy DH, Jensen RT.

Peptides. 2015 Oct;72:128-44. doi: 10.1016/j.peptides.2015.04.026. Epub 2015 May 11. Review.

44.

Neuropeptides as lung cancer growth factors.

Moody TW, Moreno P, Jensen RT.

Peptides. 2015 Oct;72:106-11. doi: 10.1016/j.peptides.2015.03.018. Epub 2015 Mar 30. Review.

PMID:
25836991
45.

CI-988 Inhibits EGFR Transactivation and Proliferation Caused by Addition of CCK/Gastrin to Lung Cancer Cells.

Moody TW, Nuche-Berenguer B, Moreno P, Jensen RT.

J Mol Neurosci. 2015 Jul;56(3):663-72. doi: 10.1007/s12031-015-0533-6. Epub 2015 Mar 12.

46.

A structure-function study of PACAP using conformationally restricted analogs: Identification of PAC1 receptor-selective PACAP agonists.

Ramos-Álvarez I, Mantey SA, Nakamura T, Nuche-Berenguer B, Moreno P, Moody TW, Maderdrut JL, Coy DH, Jensen RT.

Peptides. 2015 Apr;66:26-42. doi: 10.1016/j.peptides.2015.01.009. Epub 2015 Feb 16.

47.

EGFR Transactivation by Peptide G Protein-Coupled Receptors in Cancer.

Moody TW, Nuche-Berenguer B, Nakamura T, Jensen RT.

Curr Drug Targets. 2016;17(5):520-8. Review.

PMID:
25563590
48.

ML-18 is a non-peptide bombesin receptor subtype-3 antagonist which inhibits lung cancer growth.

Moody TW, Mantey SA, Moreno P, Nakamura T, Lacivita E, Leopoldo M, Jensen RT.

Peptides. 2015 Feb;64:55-61. doi: 10.1016/j.peptides.2014.12.005. Epub 2014 Dec 30.

49.

Important of case-reports/series, in rare diseases: Using neuroendocrine tumors as an example.

Nakamura T, Igarashi H, Ito T, Jensen RT.

World J Clin Cases. 2014 Nov 16;2(11):608-13. doi: 10.12998/wjcc.v2.i11.608.

50.

Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.

Hijioka M, Ito T, Igarashi H, Fujimori N, Lee L, Nakamura T, Jensen RT, Takayanagi R.

Cancer Sci. 2014 Nov;105(11):1464-71. doi: 10.1111/cas.12533. Epub 2014 Oct 18.

Supplemental Content

Loading ...
Support Center